PURA Rated Speculative BUY with $0.35 TGT PPS After $0.027 Close - 1000% ROI Potential
February 05 2020 - 11:19AM
InvestorsHub NewsWire
Puration
Announces Next Iteration of Ongoing CBD Consumer Survey
Results
Dallas, TX -- February 5, 2020 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced a next iteration of an ongoing CBD
consumer survey conducted by Goldman Research on behalf of PURA to
gauge and refine the company’s ongoing approach to the CBD consumer
market. This iteration of the survey specifically addressed
consumer reaction to recent negative comments from the FDA in
regard to CBD. The survey results indicated that in general,
the FDA comments have had little impact on consumer demand and that
consumer demand continues to grow.
“As we pursue a strategy to expand our
production of CBD infused beverages to include CBD infused edibles
and topicals, the CBD survey provides essential feedback,” said
PURA CEO Brian Shibley. “This iteration is particularly timely as
PURA moves closer to securing a $5 million investment to fund an aggressive
acquisition campaign to accelerate our expansion into addition
CBD infused consumer products.”
The Goldman CBD
consumer survey included a PURA speculative BUY recommendation and
at $0.35 target PPS. PURA closed yesterday at $0.29.
Realizing the target PPS could deliver a 1000%
ROI.
The full CBD consumer survey update can be
viewed at GOLDMAN CBD
SURVEY
For more information on Puration,
visit http://www.purationinc.com
Goldman has aslo recently reviewed Data443 Risk Mitigation, Inc.
(ATDS),
Alternet Systems, Inc. (ALYI)
and Exxe Group (AXXA).
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2023 to Mar 2024